The A2a/A2b receptor antagonist ZM-241385 blocks the cardioprotective effect of adenosine agonist pretreatment in in vivo rat myocardium

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 292, Issue 1, 2007, Pages

  Lasley, Robert D ^a,b   Kristo, Gentian ^a   Keith, Byron J ^a   Mentzer Jr , Robert M ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenosine receptor; Infarct reduction; Ischemia reperfusion

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 2 CHLORO 6 N CYCLOPENTYLADENOSINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 6 ETHYL 4 PROPYL 2 PHENYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG; ADENOSINE A2 RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE RECEPTOR; CARDIOTONIC AGENT; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION SIZE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; DRUG ANTAGONISM; DRUG COMBINATION; DRUG POTENTIATION; METHODOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PREMEDICATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; CARDIOTONIC AGENTS; DRUG COMBINATIONS; MALE; MYOCARDIAL ISCHEMIA; PREMEDICATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2B; RECEPTORS, ADENOSINE A2; RECEPTORS, PURINERGIC P1; TREATMENT OUTCOME; TRIAZINES; TRIAZOLES;

EID: 33846185131     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00675.2006     Document Type: Article

References (38)

1. Abe T, Morgan DA, Gutterman DD. Role of adenosine receptor subtypes in neural stunning of sympathetic coronary innervation. Am J Physiol Heart Circ Physiol 272: H25-H34, 1997.
2. Armstrong S, Ganote CE. Adenosine receptor specificity in preconditioning of isolated rabbit cardiomyocytes: evidence of A3 receptor involvement. Cardiovasc Res 28: 1049-56, 1994.
3. Auchampach JA, Jin X, Moore J, Wan TC, Kreckler LM, Ge ZD, Narayanan J, Whalley E, Kiesman W, Ticho B, Smits G, Gross GJ. Comparison of three different A1 adenosine receptor antagonists on infarct size and multiple cycle ischemic preconditioning in anesthetized dogs. J Pharmacol Exp Ther 308: 846-856, 2004.
4. Baxter GF, Hale SL, Miki T, Kloner RA, Cohen MV, Downey JM, Yellon DM. Adenosine A1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 14: 607-614, 2000.
5. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology. XXV Nomenclature and classification of adenosine receptors. Pharmacol Rev 53: 527-552, 2001.
6. Jacobson KA, Nikodijevic O, Padgett WL, Gallo-Rodriguez C, Maillard M, Daly JW. 8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett 323: 141-144, 1993.
7. 2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 280: 301-309, 1997.
8. 2A receptor-mediated striatal expression of c-fos. Eur J Neurosci 18: 296-302, 2003.
9. 2A receptor antagonist. Eur J Pharmacol 301: 107-113, 1996.
10. 2a receptor activation fails to alter cAMP or contractility: role of receptor localization. Am J Physiol Heart Circ Physiol 282: H1035-H1040, 2002.
11. 2A receptor and Erk1/2. Cardiovasc Drugs Ther 17: 415-425, 2003.
12. 2a agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 280: H1660-H1666, 2001.
13. 1 receptor mechanism. Am J Physiol Heart Circ Physiol 263: H1460-H1465, 1992.
14. Lasley RD, Narayan P, Mentzer RM Jr. New insights into adenosine receptor modulation of myocardial ischemia-reperfusion injury. Drug Dev Res 52: 357-365, 2001.
15. 3 adenosine receptor antagonists. J Med Chem 41: 3186-3201, 1998.
16. 1 receptor inhibition. Neuroscience 112: 319-329, 2002.
17. 2A adenosine receptors in the hippocampus and cortex of young adult and old rats. J Neurophysiol 82: 3196-3203, 1999.
18. 1 receptor responses. Eur J Pharmacol 383: 395-398, 1999.
19. 3 receptor activation protects the myocardium from reperfusion/reoxygenation injury. Am J Physiol Heart Circ Physiol 283: H1307-H1313, 2002.
20. 2A receptors in human and porcine cardiovascular tissues. J Pharmacol Exp Ther 286: 1051-1077, 1998.
21. Mubagwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: an updated overview. Cardiovasc Res 52: 25-39, 2001.
22. 2a receptor activation in rat heart. Am J Physiol Heart Circ Physiol 276: H341-H349, 1999.
23. 2 receptor-mediated responses in the rat hippocampus in vitro. Eur J Pharmacol 362: 17-25, 1998.
24. Ongini E, Dionisotti S, Gessi S, Irenius E, Fredholm BB. Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol 359: 7-10, 1999.
25. 2a adenosine receptor. Mol Pharmacol 48: 970-974, 1995.
26. Peart JN, Gross GJ. Adenosine and opioid receptor-mediated cardioprotection in the rat: evidence for cross-talk between receptors. Am J Physiol Heart Circ Physiol 285: H81-H89, 2003.
27. 2b receptor cascade. Cardiovasc Res 70: 308-314, 2006.
28. 2a selective adenosine receptor antagonist. Br J Pharmacol 115: 1096-1102, 1995.
29. Reid EA, Ballard-Croft C, Kristo G, Yoshimura Y, Keith BJ, Mentzer RM Jr, Lasley RD. In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling. Am J Physiol Heart Circ Physiol 288: H2253-H2259, 2005.
30. 3 receptor activation during hypoxia in isolated rat cardiac myocytes. Mol Cell Biochem 217: 143-52, 2001.
31. 2 receptor agonist AMP 579 in a porcine model of myocardial infarction. J Pharmacol Exp Ther 286: 611-618, 1998.
32. 3 receptors. J Clin Invest 98: 1773-1779, 1996.
33. 1-selective adenosine analogues protects the heart against infarction. Circulation 85: 659-665, 1992.
34. 2A receptors in the isolated murine heart. Am J Physiol Heart Circ Physiol 290: H348-H356, 2006.
35. 2 receptors. J Cardiovasc Pharmacol 38: 474-481, 2001.
36. Yang XM, Krieg T, Cui L, Downey JM, Cohen MV. NECA and bradykinin at reperfusion reduce infarction in rabbit hearts by signaling through PI3K, ERK, and NO. J Mol Cell Cardiol 36: 411-421, 2004.
37. 2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation 111: 2190-2197, 2005.
38. 3 adenosine receptor. Proc Natl Acad Sci USA 89: 7432-7436, 1992.